Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Advancing the Global Public Health Agenda for Nafld: A Consensus Statement Publisher Pubmed



Lazarus JV1, 2 ; Mark HE2 ; Anstee QM3, 4 ; Arab JP5 ; Batterham RL6 ; Castera L7 ; Cortezpinto H8 ; Crespo J9 ; Cusi K10 ; Dirac MA11 ; Francque S12, 13 ; George J14 ; Hagstrom H15 ; Huang TTK16 Show All Authors
Authors
  1. Lazarus JV1, 2
  2. Mark HE2
  3. Anstee QM3, 4
  4. Arab JP5
  5. Batterham RL6
  6. Castera L7
  7. Cortezpinto H8
  8. Crespo J9
  9. Cusi K10
  10. Dirac MA11
  11. Francque S12, 13
  12. George J14
  13. Hagstrom H15
  14. Huang TTK16
  15. Ismail MH17
  16. Kautz A18
  17. Sarin SK19
  18. Loomba R20, 21
  19. Miller V22
  20. Newsome PN23
  21. Ninburg M24
  22. Ocama P25
  23. Ratziu V26
  24. Rinella M27
  25. Romero D28
  26. Romerogomez M29
  27. Schattenberg JM30
  28. Tsochatzis EA31, 32
  29. Valenti L33, 34
  30. Wong VWS35
  31. Yilmaz Y36, 37
  32. Younossi ZM38
  33. Zelbersagi S39, 40
  34. Aberg F41, 42
  35. Adams L43
  36. Khatry MSA44
  37. Naamani KA45
  38. Murillo OA46
  39. Allen AM47
  40. Alnaser F48, 49
  41. Alqahtani SA50, 51
  42. Alswat K52
  43. Alvaro D53
  44. Andrade RJ54, 55
  45. Arrese M5
  46. Awuku YA56
  47. Ayesha M57
  48. Baatarkhuu O58
  49. Bakieva S59
  50. Basu R60
  51. Bataller R61
  52. Bedri S62
  53. Bosi E63
  54. Bourliere M64
  55. Bruha R65
  56. Bugianesi E66
  57. Burra P67
  58. Buti M68
  59. Byrne CD69
  60. Calleja JL70
  61. Carrieri P71
  62. Carter F72
  63. Fernandez MIC73
  64. Castillolopez G74
  65. Castronarro GE75, 76
  66. Chan HLY77
  67. Chan WK78
  68. Chang Y79
  69. Colombo M80
  70. Coppell KJ81
  71. Corey K82
  72. Craxi A83
  73. Cryer D84
  74. Dassanayake A85
  75. Martins AAS86
  76. De Ledinghen V87
  77. Delprato S88
  78. Demaio A89
  79. Desalegn H90
  80. Dillon J91
  81. Duseja A92
  82. Dorairaj P93
  83. Ekstedt M94
  84. El Kassas M95
  85. Elsanousi OM96
  86. Esmat G97
  87. Fan JG98
  88. Farpourlambert N99
  89. Flisiak R100
  90. Fouad Y101
  91. Fuchs M102, 103
  92. Gani RA104
  93. Gerber L105
  94. Ghazinyan H106
  95. Gheorghe L107
  96. Goh GBB108
  97. Gronbaek H109
  98. Gulnara A110
  99. Hamid S111
  100. Hebditch V112
  101. Hickman IJ113
  102. Hocking SL114
  103. Hunyady B115
  104. Idilman R116
  105. Isakov VA117
  106. Jamal MH118
  107. Jepsen P109
  108. Iskandar NJ119
  109. Song MJ120
  110. Sudhamshu KC121
  111. Kakizaki S122
  112. Kalamitsis G123
  113. Kanwal F124
  114. Kao JH125
  115. Kaplan L82
  116. Kawaguchi T126
  117. Khader Y127
  118. Kim SU128
  119. Kodjoh N129
  120. Koek G130
  121. Koike K131
  122. Komas NP132
  123. Korenjak M133
  124. Kugelmas M134
  125. Labidi A135
  126. Lange NF136
  127. Lavine JE137
  128. Lazo M138
  129. Lee N139
  130. Lesmana CRA104
  131. Liu CJ125
  132. Long MT140
  133. Lopezjaramillo P141
  134. Malekzadeh R142
  135. Mahtab MA143
  136. Marchesini G144
  137. Marinho R145
  138. Vazquez SEM76
  139. Mateva L146
  140. Nlombi CM147
  141. Melin P148
  142. Mikolasevic I149
  143. Milovanovic T150
  144. Musso C151
  145. Nakajima A152
  146. Nava E153
  147. Nersesov AV154
  148. Nikolova D155
  149. Norris S156
  150. Novak K157
  151. Oben J158
  152. Ong JP159
  153. Onyekwere C160
  154. Papatheodoridis G161
  155. Paruk I162
  156. Patel K163
  157. Macedo MP164
  158. Penhagoncalves C165
  159. Figueroa MP166
  160. Hofmann WP167
  161. Petta S83
  162. De Oliveira CPMS168
  163. Puri P102
  164. Pan CQ169
  165. Rac M170
  166. Ralston J171
  167. Ramji A172
  168. Razavi H173
  169. Alvaresdasilva MR174
  170. Roberts S175
  171. Roden M176, 177, 178
  172. Rose T179
  173. Rouabhia S180
  174. Roverequerini P181
  175. Rowe IA182
  176. Sadirova S59
  177. Salupere R183
  178. Saparbu T184
  179. Sayegh R185
  180. Sebastiani G186
  181. Seki Y187
  182. Selmo J188
  183. Serme AK189
  184. Shaw JE190
  185. Shenoy T191
  186. Sheron N192
  187. Shibolet O193
  188. Silva M194
  189. Skrypnyk I195
  190. Socha P196
  191. Soriano J197
  192. Spearman CW198
  193. Sridharan K199
  194. Suarez JJ200
  195. Sheriff DS201
  196. Sung KC202
  197. Swain M203
  198. Tacke F204
  199. Taheri S205
  200. Tan SS206
  201. Tapper EB207
  202. Ykijarvinen H42, 208, 209
  203. Thiele M210, 211
  204. Shawa IT212
  205. Tolmane I213, 214
  206. Torres EA215
  207. Trauner M216
  208. Treeprasertsuk S217
  209. Turcanu A218
  210. Valantinas J219
  211. Vesterhus M220
  212. Waked I221
  213. Wild SH222
  214. Willemse J223
  215. Wong RJ224
  216. Xanthakos S225, 226
  217. Young DY227
  218. Yu ML228
  219. Zheng KI229
  220. Zeybel M230
  221. Zheng MH229

Source: Nature Reviews Gastroenterology and Hepatology Published:2022


Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. © 2021, Springer Nature Limited.
Other Related Docs
12. Covid-19 and Mafld/Nafld: An Updated Review, Frontiers in Medicine (2023)